The aim of the present cross-sectional study was to evaluate the impact of the switch of anti-VEGF agent on visual acuity, treatment frequency and retinal morphology on OCT in eyes with ongoing chronic treatment for wet AMD. This evidence concerns the gene VEGFA and wet macular degeneration.